Bone Marrow-on-Chip as smart sensor of lung cancer relapse

What if we could uncover and foretell the basic causes of lung tumor relapse? This would provide the unprecedented opportunity to intercept patients with increased risk of relapse and to carry out not only an early intervention but also to tailor drug therapies by anticipating the specific need of each patient. Towards this vision, BuonMarrow lays on the groundbreaking hypothesis -supported by preliminary clinical evidence- that bone marrow Mesencymal Stromal Cells (BM-MSCs) from lung cancer patients posses a long-term memory-like response. In the event of a cancer relapse, they initiate a prompt and amplified response from immune cells early on. To validate such hypothesis, BuonMarrow will deliver an innovative in vitro bone marrow biological sensor (BMoC-Sense), which could predict an immune cell activation from patient lung cancer blood samples, and indicate a risk of relapse.